3317-Protocols under development

Cancer genetics - adult

ID	Protocol
4119	BARD1 – risk management
4187	AIP – genetic testing
4188	AIP – risk management
TBC	Prostate cancer – referring to genetics

ID	Protocol
TBA	10q23 deletion syndrome (Juvenile polyposis of infancy) – risk management

ID	Protocol
ID 4123	Acute myeloid leukaemia GO induction and consolidation MRC
ID 4129	Acute myeloid leukaemia GO induction and consolidation ALFA
ID 4088	Acute myeloid leukaemia STIMULus (low dose cytarabine and tioguanine) overview
ID 3987	Autologous conditioning diffuse large B-cell lymphoma with secondary CNS involvement overview
ID 3964	Multiple myeloma denosumab
ID 4084	Multiple myeloma daratumumab subcutaneous
ID 4141	Multiple myeloma selinexor and dexamethasone oral
ID 4138	Multiple myeloma elotuzumab, lenalidomide and dexamethasone
ID 4142	Multiple myeloma carfilzomib lenalidomide and dexamethasone oral
ID 4186	Multiple myeloma carfilzomib CYCLOPHOSPHamide and dexamethasone oral
ID 3645	Multiple myeloma pomalidomide CYCLOPHOSPHamide and dexamethasone oral
ID 4144	Multiple myeloma DVd (daratumumab subcutaneous bortezomib dexamethasone)
ID 4261	Myelodysplastic syndrome lenalidomide
TBC	Allogeneic conditioning aplastic anaemia CYCLOPHOSPHamide fludarabine thymoglobuline and total body irradiation (TBI)
TBC	Mantle cell lymphoma acalabrutinib
TBC	AL amyloidosis daratumumab bortezomib cyclophosphamide and dexamethasone
TBC	Hodgkin lymphoma ifosfamide, gemcitabine, vinorelbine, prednisolone (IGEV)
TBC	Multiple myeloma DRd (daratumumab subcutaneous lenalidomide dexamethasone)
TBC	Multiple myeloma D-VMP (daratumumab subcutaneous bortezomib melphalan prednisolone)
TBC	RVd 28 day protocol with once weekly bortezomib
TBC	Daunorubicin/ cytarabine (CPX 351) for AML
TBC	Decitabine/cedazuridine – MDS/ AML/ CML

ID	Protocol
3746	Gynaecological endometrium definitive EBRT
3747	Gynaecological endometrium definitive brachytherapy boost
3748	Gynaecological vulval adjuvant EBRT post-operative
3749	Gynaecological vulval definitive EBRT
3888	Head and neck nasopharynx post-induction chemotherapy EBRT chemoradiation
4000	Brain glioblastoma re-irradiation EBRT
4098	Palliative spine bone metastases stereotactic EBRT
4099	Palliative non-spinal bone metastases stereotactic EBRT
1245	Primary CNS lymphoma (PCNSL) whole brain consolidation EBRT
4140	Prostate adenocarcinoma definitive stereotactic EBRT

ID	Protocol
4061	Breast adjuvant olaparib
TBC	Breast metastatic carboplatin, gemcitabine and pembrolizumab
TBC	Breast metastatic nab-paclitaxel and pembrolizumab
TBC	Breast metastatic paclitaxel and pembrolizumab

ID	Protocol
TBC	Colorectal metastatic Raltitrexed and oxaliplatin

ID	Protocol
4169/4170	Cervical recurrent or metastatic carboplatin, paclitaxel and pembrolizumab +/- bevacizumab
TBC	Endometrical advanced or recurrent dostarlimab

ID	Protocol
TBC	Nasopharyngeal locally advanced adjuvant capecitabine
TBC	Nasopharyngeal locally advanced adjuvant cisplatin and capecitabine

ID	Protocol
TBC	Cutaneous squamous cell carcinoma pembrolizumab

ID	Protocol

ID	Protocol

ID	Protocol
4245	Ewing sarcoma recurrent or metastatic cyclophosphamide and topotecan

ID	Protocol
TBC	Oesophageal metastatic cisplatin, fluorouracil and pembrolizumab
TBC	Biliary and gallbladder advanced cisplatin gemcitabine durvalumab

ID	Protocol
TBC	Renal cell advanced or metastatic lenvatinib and pembrolizumab
TBC	Bladder intravesical docetaxel and gemcitabine
TBC	Prostate non-metastatic castration-resistant enzalutamide
TBC	Prostate metastatic castration-sensitive enzalutamide
TBC	Prostate metastatic castration-sensitive docetaxel and darolutamide

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3317

05 Feb 2023